source
- Crystalys Therapeutics raises $130M Series B to advance gout drug dotinurad toward global launchCrystalys Therapeutics announced a $130 million Series B financing to move its gout drug dotinurad through late-stage trials and prepare for commercial launch. The round was led by Frazier Life Sc…
- Eli Lilly’s $3.8 billion acquisition of AtaiBeckley signals strong backing for psychedelic therapeuticsNovartis and Roche kicked off the second‑quarter earnings season, with other majors such as AstraZeneca, GSK and Biogen slated to follow. The earnings wave highlights continued revenue growth acros…